<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00820547</url>
  </required_header>
  <id_info>
    <org_study_id>PACS09 UC-0140/0802</org_study_id>
    <secondary_id>UNICANCER-PACS-09-0802</secondary_id>
    <secondary_id>EudraCT-2008-001807-53</secondary_id>
    <secondary_id>EU-20889</secondary_id>
    <nct_id>NCT00820547</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerance Study of Bevacizumab in Her2- Inflammatory Breast Cancer Patients</brief_title>
  <acronym>Beverly1</acronym>
  <official_title>Phase II Study Evaluating the Efficacy and Tolerance of Bevacizumab (Avastin) in HER2- Inflammatory Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different
      ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
      help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy work in
      different ways to stop the growth of tumor cells, either by killing the cells or by stopping
      them from dividing. Giving bevacizumab and combination chemotherapy before surgery may make
      the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving
      bevacizumab and radiation therapy after surgery may kill any tumor cells that remain after
      surgery.

      PURPOSE: This phase II trial is studying giving bevacizumab together with chemotherapy before
      surgery and bevacizumab and radiation therapy after surgery to see how well it works in
      treating patients with inflammatory breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Evaluate the complete histological response rate in patients with inflammatory
           HER2-negative breast cancer treated with bevacizumab and concurrent chemotherapy
           followed by bevacizumab and concurrent hormonal therapy after surgery and radiotherapy.

      Secondary

        -  Evaluate the progression-fee and overall survival of these patients at 3 and 5 years.

        -  Evaluate the tolerance of bevacizumab in these patients.

        -  Assess circulating metastatic disease before, during, and after treatment.

        -  Assess circulating endothelial cells before, during, and after treatment.

        -  Assess predictive factors of response by genomic and proteomic studies on frozen tumor
           samples and fluid samples (i.e., serum and plasma).

      OUTLINE: This is a multicenter study.

        -  Neoadjuvant induction therapy:

             -  Courses 1-4: Patients receive bevacizumab IV over 30-90 minutes, fluorouracil IV,
                epirubicin hydrochloride IV over 10 minutes, and cyclophosphamide IV over 5 minutes
                on day 1.

             -  Courses 5-8: Patients receive bevacizumab IV over 30-90 minutes and docetaxel IV
                over 1 hour on day 1.

      Treatment repeats every 21 days for 8 courses in the absence of disease progression or
      unacceptable toxicity.

        -  Surgery: Patients undergo surgery 4-6 weeks after completion of bevacizumab.

        -  Adjuvant therapy: Beginning 2-4 weeks after surgery, patients undergo radiotherapy for 6
           weeks. Patients also receive bevacizumab IV over 30-90 minutes beginning 2-4 weeks after
           surgery, during the radiotherapy period. Treatment with bevacizumab repeats every 3
           weeks for 30 weeks in the absence of disease progression or unacceptable toxicity.
           Patients who are estrogen receptor- or progesterone receptor-positive (≥ 10% by IHC)
           receive the following concurrent hormonal therapy beginning in week 7:

             -  Premenopausal patients: Patients receive tamoxifen citrate for 5 years.

             -  Postmenopausal patients: Patients receive aromatase-inhibitor therapy (or tamoxifen
                citrate if unable to tolerate anti-aromatase therapy) for 5 years.

             -  Perimenopausal patients: Patients receive tamoxifen citrate for 2-3 years and
                aromatase-inhibitor therapy for 2-3 years OR tamoxifen citrate for 5 years followed
                by aromatase-inhibitor therapy for 2-3 years (if follicle-stimulating hormone &gt; 30
                IU/L and/or estradiol &lt; 30 ng/L).

      After completion of study treatment, patients are followed for at least 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete histologic response rate</measure>
    <time_frame>Post surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>3 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as assessed by CTCAE v3.0</measure>
    <time_frame>3 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive factors of response to bevacizumab</measure>
    <time_frame>3 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating peripheral cells (circulating endothelial and tumor cells): correlation of initial rate and association with histological response after surgery</measure>
    <time_frame>Post-surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genomic and proteomic analyses and correlation with histologic response</measure>
    <time_frame>Post surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>(FEC / Docetaxel) + Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant treatment: 4 cycles FEC + Bevacizumab followed by 4 cycles Docetaxel + Bevacizumab Adjuvant: Bevacizumab for 1 year</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>During neoadjuvant phase: 15 mg/kg, d1 q3w, 8 cycles During adjuvant phase:15 mg/kg, d1 q3w, 10 cycles</description>
    <arm_group_label>(FEC / Docetaxel) + Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Neoadjuvant: 500 mg/m2 d1 q3w, 4 cycles</description>
    <arm_group_label>(FEC / Docetaxel) + Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>Neoadjuvant: 100 mg/m2 q3w, 4 cycles</description>
    <arm_group_label>(FEC / Docetaxel) + Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin hydrochloride</intervention_name>
    <description>Neoadjuvant: 100 mg/m2, d1 q3w, 4 cycles</description>
    <arm_group_label>(FEC / Docetaxel) + Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <description>Neoadjuvant: 500 mg/m2, d1 q3w, 4 cycles</description>
    <arm_group_label>(FEC / Docetaxel) + Bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed inflammatory breast cancer, meeting 1 of the following
             staging criteria:

               -  T4d, any N (AJCC stage IIIB or IIIC)

               -  Gustave-Roussy Institute (IGR) classification Poussee evolutirie (PEV; measures
                  tumor growth over time) 2

                    -  PEV 2: tumor with underlying breast tissue, especially skin, that is
                       affected by subacute inflammation and edema involving &lt; ½ of breast surface

               -  IGR classification PEV 3

                    -  PEV 3: acute or subacute inflammation and edema involving &gt; ½ of breast
                       surface

               -  Biopsy-confirmed presence of tumor embolism in surface lymph nodes

          -  HER2-negative (HER2 0 or 1+, or HER2 2+ by IHC if FISH-negative allowed)

          -  No metastatic disease

          -  No non-inflammatory breast cancer with edema, ulceration, or satellite skin nodules

          -  No bilateral breast cancer

          -  Hormone receptor status known

        PATIENT CHARACTERISTICS:

          -  Any menopausal status allowed

          -  WHO performance status 0-2

          -  Life expectancy ≥ 3 months

          -  LVEF normal by ECHO

          -  ANC &gt; 1.5 x 10^9/L

          -  Platelet count &gt; 100 x 10^9/L

          -  INR ≤ 1.5 (except for patients on prophylactic anticoagulants)

          -  aPTT ≤ 1.5 times upper limit of normal (ULN)

          -  Total bilirubin normal

          -  SGOT and SGPT ≤ 1.25 times ULN

          -  Alkaline phosphatase ≤ 2.5 times ULN

          -  Creatinine clearance ≥ 60 mL/min

          -  Proteinuria &lt; 2+ or 24-hour urine protein ≤ 1 g

          -  No unhealed wound, stomach ulcer, or bone fracture

          -  No history of thrombotic or hemorrhagic disorders

          -  No significant cardiovascular disease including the following:

               -  Cerebrovascular accident within the past 6 months

               -  Unstable angina

               -  Cardiac failure

               -  Myocardial infarction

               -  Arrhythmia requiring treatment

          -  No uncontrolled hypertension (i.e., systolic BP &gt; 150 mm Hg and/or diastolic BP &gt; 100
             mm Hg)

          -  No other active infection or serious illness that would preclude patient from
             receiving study treatment

          -  No hypersensitivity to any active products or excipients of study drugs

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception during and for 6 months after
             completion of study treatment

          -  No social or psychologic reasons that would prevent study compliance or follow-up

          -  No patients who are incarcerated or on probation

        PRIOR CONCURRENT THERAPY:

          -  No prior chemotherapy, radiotherapy, or hormonal therapy for this disease

          -  More than 4 weeks since prior surgery (diagnostic biopsy or installation of implant
             allowed)

          -  More than 10 days since prior chronic non-inflammatory steroids (e.g., acetylsalicylic
             acid &gt; 325 mg/day) or platelet anticoagulation treatment (e.g., dipyridamole,
             ticlopidine, clodiprogel, cilostazol)

          -  More than 10 days since prior oral or parenteral anticoagulant or thrombolytic drugs
             (preventative thrombolytic drugs allowed)

          -  No concurrent participation in another experimental clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrice Viens, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Paoli-Calmettes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49036</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord Aquitaine</name>
      <address>
        <city>Bordeaux</city>
        <zip>33300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Lutte Contre le Cancer Georges-Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMC Les Ormeaux</name>
      <address>
        <city>Le Havre</city>
        <zip>76600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier General Andre Boulloche</name>
      <address>
        <city>Montbeliard</city>
        <zip>25209</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRLCC Nantes - Atlantique</name>
      <address>
        <city>Nantes-Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Catherine de Sienne</name>
      <address>
        <city>Nantes</city>
        <zip>02</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie Hopital</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Armoricaine De Radiologie</name>
      <address>
        <city>Saint Brieuc</city>
        <zip>F-22015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Rene Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92211</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaire de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2009</study_first_submitted>
  <study_first_submitted_qc>January 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2009</study_first_posted>
  <last_update_submitted>August 4, 2017</last_update_submitted>
  <last_update_submitted_qc>August 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>inflammatory breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>male breast cancer</keyword>
  <keyword>HER2-negative breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Inflammatory Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

